vs
Side-by-side financial comparison of Danaos Corp (DAC) and OPKO HEALTH, INC. (OPK). Click either name above to swap in a different company.
Danaos Corp is the larger business by last-quarter revenue ($262.2M vs $148.5M, roughly 1.8× OPKO HEALTH, INC.). Danaos Corp runs the higher net margin — 49.9% vs -21.1%, a 71.0% gap on every dollar of revenue. On growth, Danaos Corp posted the faster year-over-year revenue change (6.4% vs -19.2%).
Danaos Corporation is a leading global containership ownership and management firm. It operates a large fleet of modern container vessels, providing long-term charter services to top international container liner operators across major global trade routes, supporting the efficiency and reliability of global supply chains.
OPKO Health, Inc. is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".
DAC vs OPK — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $262.2M | $148.5M |
| Net Profit | $130.9M | $-31.3M |
| Gross Margin | — | 43.1% |
| Operating Margin | 47.9% | -25.8% |
| Net Margin | 49.9% | -21.1% |
| Revenue YoY | 6.4% | -19.2% |
| Net Profit YoY | -7.3% | -322.8% |
| EPS (diluted) | $7.12 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $148.5M | ||
| Q3 25 | — | $151.7M | ||
| Q2 25 | $262.2M | $156.8M | ||
| Q1 25 | — | $150.0M | ||
| Q4 24 | — | $183.6M | ||
| Q3 24 | — | $173.6M | ||
| Q2 24 | $246.3M | $182.2M | ||
| Q1 24 | — | $173.7M |
| Q4 25 | — | $-31.3M | ||
| Q3 25 | — | $21.6M | ||
| Q2 25 | $130.9M | $-148.4M | ||
| Q1 25 | — | $-67.6M | ||
| Q4 24 | — | $14.0M | ||
| Q3 24 | — | $24.9M | ||
| Q2 24 | $141.2M | $-10.3M | ||
| Q1 24 | — | $-81.8M |
| Q4 25 | — | 43.1% | ||
| Q3 25 | — | 32.9% | ||
| Q2 25 | — | 31.5% | ||
| Q1 25 | — | 28.4% | ||
| Q4 24 | — | 46.1% | ||
| Q3 24 | — | 23.1% | ||
| Q2 24 | — | 28.4% | ||
| Q1 24 | — | 24.2% |
| Q4 25 | — | -25.8% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | 47.9% | -38.3% | ||
| Q1 25 | — | -44.8% | ||
| Q4 24 | — | -18.0% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | 56.8% | -33.9% | ||
| Q1 24 | — | -41.2% |
| Q4 25 | — | -21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | 49.9% | -94.7% | ||
| Q1 25 | — | -45.1% | ||
| Q4 24 | — | 7.6% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | 57.3% | -5.7% | ||
| Q1 24 | — | -47.1% |
| Q4 25 | — | $-0.04 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | $7.12 | $-0.19 | ||
| Q1 25 | — | $-0.10 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | $7.23 | $-0.01 | ||
| Q1 24 | — | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $654.1M | $364.4M |
| Total DebtLower is stronger | — | $344.0M |
| Stockholders' EquityBook value | $3.6B | $1.3B |
| Total Assets | $4.5B | $1.9B |
| Debt / EquityLower = less leverage | — | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $364.4M | ||
| Q3 25 | — | $412.0M | ||
| Q2 25 | $654.1M | $267.3M | ||
| Q1 25 | — | $428.8M | ||
| Q4 24 | — | $426.6M | ||
| Q3 24 | — | $400.1M | ||
| Q2 24 | $471.7M | $40.6M | ||
| Q1 24 | — | $75.6M |
| Q4 25 | — | $344.0M | ||
| Q3 25 | — | $344.2M | ||
| Q2 25 | — | $343.3M | ||
| Q1 25 | — | $439.2M | ||
| Q4 24 | — | $437.2M | ||
| Q3 24 | — | $441.0M | ||
| Q2 24 | — | $201.9M | ||
| Q1 24 | — | $350.1M |
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $3.6B | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | $3.3B | $1.4B | ||
| Q1 24 | — | $1.3B |
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | $4.5B | $2.0B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | $4.0B | $2.0B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.33× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.31× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-25.9M |
| Free Cash FlowOCF − Capex | — | $-28.6M |
| FCF MarginFCF / Revenue | — | -19.3% |
| Capex IntensityCapex / Revenue | — | 1.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-190.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-25.9M | ||
| Q3 25 | — | $-34.6M | ||
| Q2 25 | — | $-83.4M | ||
| Q1 25 | — | $-34.6M | ||
| Q4 24 | — | $-44.4M | ||
| Q3 24 | — | $-77.1M | ||
| Q2 24 | — | $-26.4M | ||
| Q1 24 | — | $-35.6M |
| Q4 25 | — | $-28.6M | ||
| Q3 25 | — | $-37.8M | ||
| Q2 25 | — | $-86.7M | ||
| Q1 25 | — | $-37.7M | ||
| Q4 24 | — | $-49.8M | ||
| Q3 24 | — | $-85.0M | ||
| Q2 24 | — | $-33.7M | ||
| Q1 24 | — | $-40.0M |
| Q4 25 | — | -19.3% | ||
| Q3 25 | — | -24.9% | ||
| Q2 25 | — | -55.3% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | — | -27.1% | ||
| Q3 24 | — | -49.0% | ||
| Q2 24 | — | -18.5% | ||
| Q1 24 | — | -23.0% |
| Q4 25 | — | 1.8% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 2.9% | ||
| Q3 24 | — | 4.6% | ||
| Q2 24 | — | 4.0% | ||
| Q1 24 | — | 2.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.60× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.17× | ||
| Q3 24 | — | -3.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAC
Segment breakdown not available.
OPK
| Services | $71.1M | 48% |
| Transfer Of Intellectual Property And Other | $33.7M | 23% |
| IE | $22.1M | 15% |
| Rayaldee | $8.8M | 6% |
| Barda Agreement | $6.8M | 5% |
| MX | $6.3M | 4% |
